Last reviewed · How we verify
Recombinant Mycobacterium Tuberculosis Fusion Protein
Recombinant Mycobacterium Tuberculosis Fusion Protein is a Recombinant protein vaccine Biologic drug developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. It is currently in Phase 3 development for Tuberculosis (active disease or latent TB infection prevention). Also known as: EC.
This recombinant fusion protein combines multiple Mycobacterium tuberculosis antigens to stimulate cellular and humoral immune responses against tuberculosis infection.
This recombinant fusion protein combines multiple Mycobacterium tuberculosis antigens to stimulate cellular and humoral immune responses against tuberculosis infection. Used for Tuberculosis (active disease or latent TB infection prevention).
At a glance
| Generic name | Recombinant Mycobacterium Tuberculosis Fusion Protein |
|---|---|
| Also known as | EC |
| Sponsor | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| Drug class | Recombinant protein vaccine |
| Target | Mycobacterium tuberculosis antigens (fusion construct) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The fusion protein is engineered to present conserved TB antigens in a single immunogenic construct, designed to enhance T-cell and B-cell recognition of Mycobacterium tuberculosis. By combining multiple epitopes, it aims to broaden immune coverage and improve protection against active TB disease and/or latent TB infection reactivation.
Approved indications
- Tuberculosis (active disease or latent TB infection prevention)
Common side effects
- Injection site reactions (pain, erythema, induration)
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults (PHASE3)
- Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above (PHASE3)
- Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV (PHASE2)
- Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above (PHASE3)
- Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein (PHASE4)
- Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis (PHASE1)
- A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) (PHASE2)
- Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Mycobacterium Tuberculosis Fusion Protein CI brief — competitive landscape report
- Recombinant Mycobacterium Tuberculosis Fusion Protein updates RSS · CI watch RSS
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. portfolio CI
Frequently asked questions about Recombinant Mycobacterium Tuberculosis Fusion Protein
What is Recombinant Mycobacterium Tuberculosis Fusion Protein?
How does Recombinant Mycobacterium Tuberculosis Fusion Protein work?
What is Recombinant Mycobacterium Tuberculosis Fusion Protein used for?
Who makes Recombinant Mycobacterium Tuberculosis Fusion Protein?
Is Recombinant Mycobacterium Tuberculosis Fusion Protein also known as anything else?
What drug class is Recombinant Mycobacterium Tuberculosis Fusion Protein in?
What development phase is Recombinant Mycobacterium Tuberculosis Fusion Protein in?
What are the side effects of Recombinant Mycobacterium Tuberculosis Fusion Protein?
What does Recombinant Mycobacterium Tuberculosis Fusion Protein target?
Related
- Drug class: All Recombinant protein vaccine drugs
- Target: All drugs targeting Mycobacterium tuberculosis antigens (fusion construct)
- Manufacturer: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Tuberculosis (active disease or latent TB infection prevention)
- Also known as: EC
- Compare: Recombinant Mycobacterium Tuberculosis Fusion Protein vs similar drugs
- Pricing: Recombinant Mycobacterium Tuberculosis Fusion Protein cost, discount & access